Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. - Wikidata - awgldk - TriplyDB

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

http://www.wikidata.org/entity/Q34496962

about

Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine.Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease European evidence-based Consensus on the management of ulcerative colitis: Current management.Optimum dose of olsalazine for maintaining remission in ulcerative colitis.Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion Microscopic activity in ulcerative colitis: what does it mean?Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis Drug therapy of ulcerative colitis Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time.Azo reduction of sulphasalazine in healthy volunteers Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls.Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis.Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study Review article: monitoring for drug side-effects in inflammatory bowel disease.Review article: maintenance of remission in ulcerative colitis.Five-aminosalicylic Acid: an update for the reappraisal of an old drug Effect of reactive pharmacy intervention on quality of hospital prescribing Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.Sulphasalazine in ulcerative colitis: in memoriam?The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine A double-blind controlled trial of the effect of sodium cromoglycate in preventing relapse in ulcerative colitis.Second Korean guidelines for the management of ulcerative colitis.Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis.An evidence-based systematic review on medical therapies for inflammatory bowel disease.Medical treatment of ulcerative colitis.Nonabsorbable food additives through polymeric design.The effect of salicylazosulphapyridine (sulphasalazine) on male fertility. A review.Sulfasalazine and related new drugs.Medical treatment of ulcerative colitis: scoring the advances.Drug therapy of inflammatory bowel disease.Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides.Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis.Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?The effect of the acetylator phenotype on the metabolism of sulphasalazine in man.Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.Proctocolitis induced by salicylate and associated with asthma and recurrent nasal polyps Is mesalamine safe?

P2860

Q28205383-83166357-2A53-4EDD-B7E9-23F4EFDDFB41 Q33561669-36E8D7C7-0A99-48CB-8777-723413F4B660 Q33562841-A1F29A4A-D031-42F9-AC31-A43252D48104 Q34025054-394C346B-13DC-4F14-B527-F7D8B36468C8 Q34382072-E62505DB-5655-4064-9485-8FBE324B4D15 Q34393049-894B5F0E-FA95-43B2-96EB-B91D2608B9F8 Q34393414-EE8CD16D-B12F-4F69-8034-9F50CF49E7B9 Q34394096-0BECD6A7-3761-4B62-A34E-64493848931A Q34403155-82268174-4A65-421A-83F7-1CEFA3185E8B Q34416779-A7B2C6B2-92CB-4EFC-A215-69126FAE7CE5 Q34511854-F8EC32AF-88BC-4F05-9A5A-2D12E84B827D Q34525348-F3DC245F-249A-478D-9590-C236946E54DE Q34530099-DF897773-ECFE-4D85-8CDC-F66BB9795DBE Q34530593-89BE0358-F38E-4262-9696-12AC5E25C9ED Q34532266-A3C56EE8-2CCF-458B-B054-6A8E97B808BC Q34585315-354141B0-DEF3-40A5-8620-15E9AEE93016 Q34669207-C8F4FF0E-909D-4736-9976-127BE067E5D6 Q35061210-4C1028D3-0716-4105-90BC-97E2D5C4DD9E Q35168691-A89CED48-193E-4D65-9021-CC4B7DB3EBBB Q35361187-923DF805-4516-4B07-839A-FDA0E07EA0F2 Q36495618-AA2D5E81-7420-4E39-B687-05D292642AEE Q36706817-EF083B20-7932-41A0-853E-85C249A5C5D8 Q36714570-577D3652-F48C-47E1-A706-479BD8FB59BE Q37662503-21091644-15F8-438F-8520-8BA30B7499DD Q37853364-A579969E-ED6C-4DC7-8F23-73DBE01A7C5A Q37862584-06C737DF-25CA-4B84-8FB1-2B6838AFBA4D Q38938913-557DC484-A413-41DA-BDA2-FC7BF592825F Q39455530-B497CA75-F7AC-4EEF-81F2-6EB70E53996B Q39459955-289C1B4F-23AA-4C6D-BB83-053DA86EC108 Q39464997-9329E1D6-0A3D-43DE-BEAB-A639F6A911EF Q39545180-F71CB101-DA04-4E08-BD7F-5BAFBEB9434A Q40090889-C9C9D09A-CB35-480C-ACD6-78BF23C237B8 Q40794512-F8B52FC9-BBA8-45EB-99D5-926C8B9E7955 Q41150439-0D57E4B1-5DE4-47D7-A87C-CA5BD64F0DAA Q41858227-BADECC0F-5340-45E8-A6AA-F0EDB8BD9F87 Q41903886-F9AD3772-24CE-426C-9DAF-5225679F1A1E Q42008549-6AC95F81-B792-460F-A33D-693D2664C6F5 Q42086297-4311E0C9-9E8B-4339-8142-1599F2FA4D13 Q42119664-0E91C0F2-B99E-4430-9A82-E295A14F986D Q42140692-E896E9B8-86D0-48CA-96DB-032C0FB61CC3

P2860

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

http://www.wikidata.org/entity/Q34496962

description

1980 nî lūn-bûn

@nan

1980 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

1980 թվականի մարտին հրատարակված գիտական հոդված

@hy

1980年の論文

@ja

1980年学术文章

@wuu

1980年学术文章

@zh-cn

1980年学术文章

@zh-hans

1980年学术文章

@zh-my

1980年学术文章

@zh-sg

1980年學術文章

@yue

name

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

@ast

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

@en

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

@nl

type

label

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

@ast

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

@en

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

@nl

prefLabel

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

@ast

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

@en

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

@nl

P1433

Q34496962-EE4E0A0E-6EA5-4FE2-A45B-AB275C8BE450

P1476

Q34496962-030EB347-F0D7-43F7-A5D4-0EEA84ADD18D

P2093

Q34496962-200C5E8E-C789-444B-B195-FB1B58D33205

Q34496962-409CFB2A-250D-4603-BA26-A2ACDEEEA0E3

Q34496962-C82BCF5B-3510-418C-A842-75FC2971A641

Q34496962-EB935171-1C44-4B3D-82C1-E2D9B61CEFEF

P2860

Q34496962-2B181D98-E8E0-407D-BF5A-0DFDB68CCE94

Q34496962-332E4622-5B59-4FB9-9BCB-19D870C59DE0

Q34496962-339EA6FB-AACE-44E3-8491-34E55EF3C2EA

Q34496962-453D7F38-97CF-4A0D-A322-EE4B603742D2

Q34496962-48D02190-424F-4182-B16E-6D8520DA9F6A

Q34496962-533D52A3-F380-45C7-A85F-D9E65B1F0AF6

Q34496962-59CC8FCC-CBE8-465C-889C-F6AE2F4FDE28

Q34496962-66B2A749-35E0-41B9-A459-FD10467D0106

Q34496962-7CB3E46D-F88C-4028-81B9-0A7A3F8F275E

Q34496962-8016A241-4534-4F24-91E6-C112F4ED3500

P304

Q34496962-DD1182CE-8156-406A-8EBB-FC96C13AD8E3

P31

Q34496962-43C9F49F-A733-4A6A-97E3-FDC9DCF4E53A

P356

Q34496962-E8A8F5A1-629F-4BE7-8E16-8CE499879F78

P407

Q34496962-00485BF9-BB3D-48D7-88BD-D8BFD349EAE9

P433

Q34496962-A3B1E0E0-E949-4630-BFF4-550D778B3AD2

P478

Q34496962-F47B95FC-7663-4FD5-8F1A-583AF58535B5

P577

Q34496962-E87B793D-DB01-4C68-A7DF-54B80C2CCFF2

P5875

Q34496962-F6386FC4-1E36-44AF-9E79-552020DA33E6

P698

Q34496962-48DDB39A-9AE6-4DA8-B6DA-6678FA02A87E

P932

Q34496962-D843EF48-FDC5-4780-8027-4D0A712606A5

P356

P1433

P1476

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

@en

P2093

Azad Khan AK

http://www.w3.org/2001/XMLSchema#string

Howes DT

http://www.w3.org/2001/XMLSchema#string

Piris J

http://www.w3.org/2001/XMLSchema#string

Truelove SC

http://www.w3.org/2001/XMLSchema#string

P2860

Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis.

A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

An improved and simplified method of detecting the acetylator phenotype

Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects.

Further studies on the properties and assay of glucose 6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase of rat liver.

The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients

Peripheral neuritis due to isoniazid.

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

Adverse reactions to salicylazosulfapyridine (azulfidine) in the treatment of ulcerative colitis.

An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis.

P304

232-240

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.21.3.232

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

1980-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

17081429

http://www.w3.org/2001/XMLSchema#string

P698

6105118

http://www.w3.org/2001/XMLSchema#string

P932

1420362

http://www.w3.org/2001/XMLSchema#string